Prediction of ARrhythmic Events With Positron Emission Tomography II (PAREPET II)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: John M Canty, MD
- Phone Number: (716) 829-2663
- Email: canty@buffalo.edu
Study Contact Backup
- Name: James A Fallavollita, MD
- Phone Number: (716) 829-2663
- Email: jaf7@buffalo.edu
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14214
- University at Buffalo Clinical and Translational Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Coronary artery disease (by cardiac catheterization or definite myocardial infarction)
- ICD implantation for the primary prevention of SCA
Primary prevention patients with a Biventricular ICD
- Eligible immediately when this is placed to prevent dysynchrony related to intermittent RV pacing and the native QRS duration is ≤ 130 msec in the absence of pacing.
- Eligible 6 months after implantation when the native QRS duration prior to implant is >130 msec or there is persistent RV pacing.
- Optimal medical therapy for heart failure.
Exclusion Criteria:
- Plans for coronary revascularization (due to the independent impact on SCA)
- Contraindication for PET (i.e. claustrophobia, pregnancy, physical limitation)
- Tricyclic antidepressant use (inhibits norepinephrine and LMI1195 uptake)
- Comorbidities limiting life expectancy <2yr.
- Age <18 years or inability to provide informed consent
- Primary prevention ICD/BiV recipients who have received an appropriate ICD shock prior to enrollment
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sudden Cardiac Arrest Events
Time Frame: Through study completion, an average of 3 years
|
The primary end-point will be SCA or ICD equivalent as used in PAREPET.
This will consist of ICD therapies for ventricular fibrillation or ventricular tachycardia >240 bpm, and adjudicated arrhythmic death using the modified Hinkle-Thaler criteria.
|
Through study completion, an average of 3 years
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All cause cardiac mortality
Time Frame: Through study completion, an average of 3 years
|
Adjudicated total cardiac mortality (SCA + non-sudden cardiac death).
|
Through study completion, an average of 3 years
|
|
All appropriate ICD therapies
Time Frame: Through study completion, an average of 3 years
|
Adjudicated appropriate ICD therapies (ICD shock and anti-tachycardia pacing) for ventricular arrhythmias.
Appropriate ICD therapies will be determined from ICD device interrogation.
|
Through study completion, an average of 3 years
|
|
Hospitalization for heart failure and myocardial infarction.
Time Frame: Through study completion, an average of 3 years
|
Interval hospitalizations for heart failure or myocardial infarction will be assessed via phone follow-up at 3 month intervals.
Subjects having either will be invited to return for a repeat PET scan, echocardiogram and serum sampling to assess whether the underlying substrate for arrhythmogenesis has changed.
|
Through study completion, an average of 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: John M Canty, MD, University at Buffalo
Publications and helpful links
General Publications
- Fallavollita JA, Dare JD, Carter RL, Baldwa S, Canty JM Jr. Denervated Myocardium Is Preferentially Associated With Sudden Cardiac Arrest in Ischemic Cardiomyopathy: A Pilot Competing Risks Analysis of Cause-Specific Mortality. Circ Cardiovasc Imaging. 2017 Aug;10(8):e006446. doi: 10.1161/CIRCIMAGING.117.006446.
- Malhotra S, Canty JM Jr. Life-Threatening Ventricular Arrhythmias: Current Role of Imaging in Diagnosis and Risk Assessment. J Nucl Cardiol. 2016 Dec;23(6):1322-1334. doi: 10.1007/s12350-015-0392-0. Epub 2016 Jan 15.
- Goldberger JJ, Basu A, Boineau R, Buxton AE, Cain ME, Canty JM Jr, Chen PS, Chugh SS, Costantini O, Exner DV, Kadish AH, Lee B, Lloyd-Jones D, Moss AJ, Myerburg RJ, Olgin JE, Passman R, Stevenson WG, Tomaselli GF, Zareba W, Zipes DP, Zoloth L. Risk stratification for sudden cardiac death: a plan for the future. Circulation. 2014 Jan 28;129(4):516-26. doi: 10.1161/CIRCULATIONAHA.113.007149. No abstract available.
- Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldwa S, Mashtare TL Jr, Hutson AD, Dekemp RA, Haka MS, Sajjad M, Cimato TR, Curtis AB, Cain ME, Canty JM Jr. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2014 Jan 21;63(2):141-9. doi: 10.1016/j.jacc.2013.07.096. Epub 2013 Sep 25.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HL-130266
- R01HL130266-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.